

Table S2. Clinical Outcomes at 2-weeks Post-arthroplasty within CYP2D6 PM/IMs and NMs

	CYP2D6-guided	Usual Care	P values
MME Consumption			
PM/IM	220 mg [104-336] (n=29)	275 mg [163-335] (n=23)	0.338
NM	186 mg [104-269] (n=96)	225 mg [120-350] (n=41)	0.174
NM/UM	-	160 mg [125-310] (n=3)	-
Composite Pain Intensity			
PM/IM	2.5 ± 0.8 (n=30)	2.5 ± 0.5 (n=25)	0.800
NM	2.6 ± 0.8 (n=106)	2.6 ± 0.8 (n=45)	0.972
NM/UM	-	2.3 ± 1.5 (n=3)	-
MME: morphine milligram equivalents; Values displayed as median [interquartile range] or mean ± SD. Composite pain intensity was defined as the mean of current pain, and worst and average pain over the past seven days, each assessed on a 5-point Likert scale.			

Table S3. Clinical Outcomes at 1-week Post-arthroplasty

	CYP2D6-guided	Usual Care	P values
MME Consumption	95 mg [55 – 168] (n=111)	125 mg [75 – 200] (n=57)	0.073
Composite Pain Intensity	2.9 ± 0.9 (n=133)	2.9 ± 0.7 (n=67)	0.943

MME: morphine milligram equivalents; Values displayed as median [interquartile range] or mean ± SD. Composite pain intensity was defined as the mean of current pain, and worst and average pain over the past seven days, each assessed on a 5-point Likert scale.

Table S5. HOOS-JR and KOOS-JR Interval Scores at 2-weeks Post-arthroplasty

	CYP2D6-guided	Usual Care	P values
HOOS (n=82)			
Mean ± SD	69 ± 17 (n=54)	69 ± 16 (n=28)	0.997
PM/IM	68 ± 16 (n=12)	64 ± 9 (n=6)	0.621
NM	70 ± 18 (n=41)	69 ± 17 (n=21)	0.846
NM/UM	-	100 (n=1)	-
KOOS (n=111)			
Mean ± SD	59 ± 15 (n=74)	62 ± 12 (n=37)	0.455
PM/IM	55 ± 15 (n=16)	62 ± 12 (n=16)	0.163
NM	61 ± 15 (n=58)	62 ± 12 (n=19)	0.681
NM/UM	-	53 ± 19 (n=2)	-

Values displayed as mean ± SD. The HOOS-JR and KOOS-JR interval scores range from 0 to 100 where 0 represents total hip or knee disability and 100 represents perfect hip or knee health.